The Technology Helping Existing FDA-Approved Drugs Target More Effectively

The Technology Helping Existing FDA-Approved Drugs Target More Effectively

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Travis Mickle, President and CEO of KemPharm, Inc. KMPH, was a guest speaker at Benzinga’s All Access on April 29th, 2022. 

KemPharm is a pharmaceutical company boasting proprietary technologies that help improve the potential benefits and properties of existing FDA-approved drugs.

Watch the full interview. 

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Photo by Adam Nieścioruk on Unsplash

Posted In: Benzinga All AccessKemPharmBiotechPenny StocksHealth CareGeneral